IOV-3001
- Generic Name
- IOV-3001
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1
Recruiting
- Conditions
- Unresectable MelanomaMetastatic MelanomaOcular Melanoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT06940739
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath